Journal of Molecular Structure, cilt.1338, 2025 (SCI-Expanded, Scopus)
A promising novel drug candidate, 2‑methoxy-4-[((3-methyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl)-imino)-methyl]-phenyl benzoate (3), has been successfully synthesized through the condensation reaction of 4-formyl-2-methoxyphenyl benzoate and 4-amino-5-methyl-2,4-dihydro-3H-1,2,4-triazol-3-one. The synthesis process demonstrated a good yield, and the compound underwent thorough characterization using 1H\13C NMR, IR, and UV–Vis spectroscopic techniques. A newly synthesized compound, 2‑methoxy-4-(((3-methyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl)-imino)-methyl)-phenyl benzoate (3), has been performed structural analysis utilizing a combination of experimental and theoretical methods. The analysis process involved the use of FT-IR and NMR spectroscopy alongside the evaluation of various electronic parameters, including global reactivity parameters, FMO, NBO, MEP, ELF, LOL, TDM, NLO, and UV, using the IEFPCM model. A comprehensive molecular docking study was conducted to analyze the binding mode interactions between compound 3 and the targeted enzymes (AChE, BChE, COX-1, and COX-2). The results indicate that the strength of intermolecular hydrogen bonding in ligand-receptor complexes is crucial in explaining the observed inhibition outcomes. Furthermore, molecular dynamics simulations are conducted to analyze the protein-ligand complex and assess the stability of the compound within a protein environment.